Drug intelligence / Profile preview

synthetic shared-neoantigen biological vaccine

Development stage: Unknown
Lead developer: Nanjing Drum-Tower Hospital
Modality: Vaccines & Immunotherapeutics
Administration: Intravenous, Intramuscular, Subcutaneous

Overview

The synthetic shared-neoantigen biological vaccine is a biological product designed for cancer immunotherapy. It targets shared neoantigens, which are unique tumor-specific antigens arising from mutations in cancer cells. The vaccine aims to stimulate the immune system to recognize and eliminate cancer cells, particularly in advanced solid tumors characterized by TP53 or KRAS gene mutations. It is being investigated in clinical trials, often in combination with anti-PD(L)1 antibodies, to enhance anti-tumor immune responses.

Other names: 共享新抗原合成生物疫苗

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on synthetic shared-neoantigen biological vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on synthetic shared-neoantigen biological vaccine.

Explore the full profile